Pfizer reports a drug-related death in tofacitinib trial

04/21/2011 | Wall Street Journal, The

Pfizer confirmed that one of four deaths during a clinical study of tofacitinib, a drug candidate for rheumatoid arthritis, was related to the drug. The company said tofacitinib-related mortality across several trials "is within the range of rates reported for biologic therapies" for the condition. Pfizer aims to market tofacitinib as an alternative to infused or injected treatments, such as Abbott Laboratories' Humira.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA